Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

Aim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-order Monte Carlo simulatio...

Descripción completa

Detalles Bibliográficos
Autores: Casado, E, Rosas, J, Rubio-Terrés, C, Rubio-Rodríguez, D, Boolell, M, Arístegui, I
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4248
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/4248
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175585014&doi=10.57264%2fcer-2023-0115&partnerID=40&md5=822985ff092227834b4d9eb1b01b99db
Access Level:acceso abierto
Palabra clave:alendronate
cost-effectiveness
postmenipausal osteoporosis
risedronate gastro-resistant
id ES_3ffd23a673eb84864097c097adfd5321
oai_identifier_str oai:i3pt.fundanetsuite.com:p4248
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in SpainCasado, ERosas, JRubio-Terrés, CRubio-Rodríguez, DBoolell, MArístegui, Ialendronatecost-effectivenesspostmenipausal osteoporosisrisedronate gastro-resistantAim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-order Monte Carlo simulation) was performed with a time horizon of 5 years, from the perspective of the Spanish National Health System. The bone fracture probabilities were obtained from a cohort study of 3614 women from USA with PMO treated with RIS-GR (1807) or ALN (1807) (Thomasius, 2022). The pharmacological cost and the cost of fractures were obtained from Spanish sources (euro 2022). The utilities of patients with and without fracture (quality adjusted life years [QALYs]) were obtained from the medical literature. Results: Compared with ALN, treatment with RIS-GR can avoid 79 fractures (between 75 and 82) every 1000 patients treated, and 0.0119 QALYs would be gained (between 0.0098 and 0.0140) per patient. Additionally, GR-RIS would generate a cost saving per patient of euro1994 (euro1437-2904) with a probability of 99.7%. The scenario analyses confirmed the stability of the base case results. Conclusion: According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN.Becaris Publishing2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4248https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175585014&doi=10.57264%2fcer-2023-0115&partnerID=40&md5=822985ff092227834b4d9eb1b01b99dbJournal of Comparative Effectiveness ResearchISSN: 20426305ISSNe: 20426313reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p42482026-06-21T15:30:37Z
dc.title.none.fl_str_mv Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
title Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
spellingShingle Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
Casado, E
alendronate
cost-effectiveness
postmenipausal osteoporosis
risedronate gastro-resistant
title_short Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
title_full Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
title_fullStr Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
title_full_unstemmed Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
title_sort Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
dc.creator.none.fl_str_mv Casado, E
Rosas, J
Rubio-Terrés, C
Rubio-Rodríguez, D
Boolell, M
Arístegui, I
author Casado, E
author_facet Casado, E
Rosas, J
Rubio-Terrés, C
Rubio-Rodríguez, D
Boolell, M
Arístegui, I
author_role author
author2 Rosas, J
Rubio-Terrés, C
Rubio-Rodríguez, D
Boolell, M
Arístegui, I
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv alendronate
cost-effectiveness
postmenipausal osteoporosis
risedronate gastro-resistant
topic alendronate
cost-effectiveness
postmenipausal osteoporosis
risedronate gastro-resistant
description Aim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-order Monte Carlo simulation) was performed with a time horizon of 5 years, from the perspective of the Spanish National Health System. The bone fracture probabilities were obtained from a cohort study of 3614 women from USA with PMO treated with RIS-GR (1807) or ALN (1807) (Thomasius, 2022). The pharmacological cost and the cost of fractures were obtained from Spanish sources (euro 2022). The utilities of patients with and without fracture (quality adjusted life years [QALYs]) were obtained from the medical literature. Results: Compared with ALN, treatment with RIS-GR can avoid 79 fractures (between 75 and 82) every 1000 patients treated, and 0.0119 QALYs would be gained (between 0.0098 and 0.0140) per patient. Additionally, GR-RIS would generate a cost saving per patient of euro1994 (euro1437-2904) with a probability of 99.7%. The scenario analyses confirmed the stability of the base case results. Conclusion: According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/4248
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175585014&doi=10.57264%2fcer-2023-0115&partnerID=40&md5=822985ff092227834b4d9eb1b01b99db
url https://i3pt.portalinvestigacion.com/publicaciones/4248
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175585014&doi=10.57264%2fcer-2023-0115&partnerID=40&md5=822985ff092227834b4d9eb1b01b99db
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Becaris Publishing
publisher.none.fl_str_mv Becaris Publishing
dc.source.none.fl_str_mv Journal of Comparative Effectiveness Research
ISSN: 20426305
ISSNe: 20426313
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406704936943616
score 15,811543

Similares en LA Referencia